Cargando…

Association Between Parafibromin Expression and Presence of Brown Tumors and Jaw Tumors in Patients with Primary Hyperparathyroidism: Series of Cases with Review of the Literature

Case series Patients: Male, 57-year-old • Male, 42-year-old • Female, 45-year-old • Male, 42-year-old Final Diagnosis: Brown tumor • hyperparathyroidism Symptoms: Brown tumor • hypercalcemia Medication: — Clinical Procedure: — Specialty: Endocrinology and Metabolic OBJECTIVE: Rare disease BACKGROUND...

Descripción completa

Detalles Bibliográficos
Autores principales: Popow, Michał, Kaszczewska, Monika, Góralska, Magdalena, Kaszczewski, Piotr, Skwarek-Szewczyk, Agata, Chudziński, Witold, Jażdżewski, Krystian, Kolanowska, Monika, Bogdańska, Magdalena, Starzyńska-Kubicka, Aleksandra, Gałązka, Zbigniew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597261/
https://www.ncbi.nlm.nih.gov/pubmed/36271606
http://dx.doi.org/10.12659/AJCR.936135
Descripción
Sumario:Case series Patients: Male, 57-year-old • Male, 42-year-old • Female, 45-year-old • Male, 42-year-old Final Diagnosis: Brown tumor • hyperparathyroidism Symptoms: Brown tumor • hypercalcemia Medication: — Clinical Procedure: — Specialty: Endocrinology and Metabolic OBJECTIVE: Rare disease BACKGROUND: Brown and jaw tumors are rare entities of poorly understood etiology that are regarded as end-stage of bone remodeling in patients with long-lasting and chronic hyperparathyroidism. Jaw tumors are mainly diagnosed in jaw tumors syndrome (HPT-JT syndrome) and are caused by mutation in the CDC73 gene, encoding parafibromin, a tumor suppressing protein. The aim of this work is to present 4 cases of patients in whom the genetic mutation of the CDC73 gene and clinical presentation coexist in an unusual setting that has not yet been described. CASE REPORTS: We present cases of 4 patients with primary hyperparathyroidism. Three were diagnosed with brown tumors (located in long bones, ribs, iliac, shoulders) and 1 with brown and jaw tumors. Expression of parafibromin in affected parathyroid tissues were analyzed. In patients without positive parafibromin staining, we searched for CDC73 mutation using next-generation sequencing. Parafibromin staining was positive in 1 patient with brown tumors and was negative in 2 individuals with brown tumors and 1 with brown and jaw tumors. CDC73 mutation was detected in two-thirds of patients (60%) with negative staining for parafibromin and brown tumors. MEN1 mutation was found in the patient with brown tumor and positive staining for parafibromin. CONCLUSIONS: Patients with hyperparathyroidism and coexistence of brown tumors or jaw tumors might have decreased expression of parafibromin in parathyroid adenoma tissue, which might be caused by CDC73 mutation and suggest a genetic predisposition. Further research on much larger study groups is needed.